




24729

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 9/02, 15/00, 15/11 C12N 15/53, 15/70, 15/74		A1	(11) International Publication Number: WO 92/15673
			(43) International Publication Date: 17 September 1992 (17.09.92)
(21) International Application Number: PCT/US91/01614		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(22) International Filing Date: 11 March 1991 (11.03.91)			
(71) Applicant: THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602 (US).		Published With international search report.	
(72) Inventors: CORMIER, Milton, Joseph ; Route 1, Box 34A, Bogart, GA 30622 (US). LORENZ, William, Walter ; 217 North Avenue, Athens, GA 30601 (US).			
(74) Agents: NEELEY, Richard, L. et al.; Cooley Godward Castro Huddleson & Tatum, 5 Palo Alto Square, 4th Floor, Palo Alto, CA 94306 (US).			

(54) Title: CLONING AND EXPRESSION OF RENILLA LUCIFERASE



(57) Abstract

Genetic material encoding luciferase from the marine coelenterate *Renilla* has been isolated and characterized. This genetic material allows the production of peptides for use as labels in bioluminescence assays or can itself be directly used to identify luciferase genes from related organisms.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

CLONING AND EXPRESSION OF RENILLA LUCIFERASE

5

BACKGROUND OF THE INVENTIONField of the Invention

- 10 This invention relates to the field of genetic engineering and is particularly related to the expression of proteins by techniques involving genetic engineering.

15 Description of the Background

- The Renilla, also known as sea pansies, belong to a class of coelenterates known as the anthozoans. In addition to Renilla, other representative bioluminescent genera of the class Anthozoa include
- 20 Cavarnularia, Ptilosarcus, Stylatula, Acanthoptilum, and Parazoanthus. All of these organisms are bioluminescent and emit light as a result of the action of an enzyme (luciferase) on a substrate (luciferin) under appropriate biological conditions. Prior studies
- 25 have demonstrated that all of the above-mentioned anthozoans contain similar luciferases and luciferins. See, for example, Cormier et al., J. Cell. Physiol. (1973) 81: 291-298. The luciferases and luciferins from each of these anthozoans will cross-
- 30 react with one another to produce the characteristic blue luminescence observed in Renilla extracts. Each of these luciferases has similar biochemical properties, and the biochemical requirements for bioluminescence are identical regardless of the
- 35 anthozoan from which the luciferase was derived.

 There has been considerable interest of late in replacing radioactive labels used in analytical

assays with other types, such as luminescent labels. Firefly luciferase, which is a molecule of significantly different structure that does not react with Renilla-like luciferins, is one molecule that has
5 been proposed for use as such labels. However, firefly luciferase suffers from a number of deficiencies that make this molecule less than optimal in biological assays. For example, ATP acts as a trigger of the firefly luciferase system, and the ubiquitous nature of
10 ATP makes control of this variable difficult.

A prior patent application by one of the present inventors, U.S. Patent Application Serial No. 059,137, filed June 5, 1987, describes use of
15 coelenterate-derived luciferases and photoproteins as bioluminescent labels. Other applications by the same inventor, for example, U.S. Application Serial Nos. 173,045, filed March 17, 1988, and 165,422, filed February 29, 1988, describe recombinant DNA capable of expressing the photoprotein apoaquorin.

20 The photoprotein aequorin (which consists of apoaquorin bound to a coelenterate luciferin molecule) and Renilla luciferase both utilize the same coelenterate luciferin, and the chemistry of light emission in both cases has been shown to be the same.
25 However, aequorin luminescence is triggered by calcium, does not require dissolved oxygen, and represents a single turnover event. In contrast, Renilla luciferase is not triggered by calcium and requires dissolved oxygen in order to produce light in the presence of
30 coelenterate luciferin. Renilla luciferase also acts as a true enzyme, catalyzing a long-lasting luminescence in the presence of saturating levels of luciferin.

Sub-attomole levels of aequorin can be
35 detected with photometers even though its luminescence represents a single turnover event. Renilla luciferase, because of its enzymatic ability, should be

detectable at levels 1 to 2 orders of magnitude lower than aequorin. Furthermore, Renilla luciferase is known to be relatively stable to heat, an important consideration for assays that often involve incubation at physiological temperatures. Accordingly, Renilla luciferase is a potentially useful label for biological and other assays.

On the other hand, Renilla live on the ocean bottom, about 30 to 100 feet deep, and must be collected by dredging. From 1 kg of Renilla (about 1000 animals), approximately 1 mg of pure Renilla luciferase can be obtained following a tedious procedure which requires purifying the protein about 12,000 fold. The purification procedure is described in Matthews et al., Biochemistry (1977) 16: 85-91. As a result, there has been no development of Renilla luciferase as a detectable label.

Accordingly, improved techniques for the production of pure Renilla luciferase are necessary before this molecule can be used commercially in bioluminescence assays.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be better understood by reference to the following detailed description and examples and the attached Figures that form part of the present specification, wherein:

Figure 1 is the nucleotide sequence of a clone that contains a Renilla reniformis luciferase cDNA sequence.

Figure 2 is the amino acid sequence derived from the open reading frame of the Renilla luciferase cDNA shown in Figure 1.

Figure 3 is the recombinant luciferase amino acid sequence with different types of underlining to show the location of peptides obtained by digestion of native luciferase with V-8 protease.

Figure 4 is a table showing the amino acid sequence of Renilla reniformis peptides obtained by V-8 protease digestion. Regions of low degeneracy that were selected for preparation of oligonucleotide probes are shown by boxes. The probes are shown at the bottom part of the Figure.

Figure 5 is a schematic representation of a restriction enzyme map for Renilla luciferase cDNA. The lower portion of Figure 5 is a schematic representation of sequencing strategy for Renilla luciferase cDNA.

Figure 6 is a map of a Renilla luciferase expression plasmid.

Figure 7 is a schematic diagram of the control region of the plasmid pTZRLuc-1.

Figure 8 is a schematic diagram of the purification scheme used to purify recombinant luciferase.

20

SUMMARY OF THE INVENTION

The present invention provides genetic material encoding Renilla luciferase. The genetic material can be used to produce the enzyme for use as luminescent tags in bioluminescence assays and for other purposes for which such labels are desirable. Additionally, the genetic material can be used as a source of probes that can be used in nucleic acid hybridization assays for the identification of other luciferase genes from related organisms. Fragments of the enzyme can be used to prepare antibodies for the purpose of identifying luciferase genes from related organisms. Specific genetic materials and luciferase proteins are disclosed in the following detailed description and examples.

35

DESCRIPTION OF SPECIFIC EMBODIMENTS

The present inventors have identified and obtained for the first time genetic material encoding luciferase from the coelenterate genus Renilla which previously has been available only in limited quantities. Since luciferases have a number of uses as a bioluminescent label and since Renilla luciferase has a number of properties that make it particularly useful as a label, availability of the enzyme in significant quantities in pure form provides a significant commercial advantage over prior sources. The Renilla genetic material also provides a source of nucleic acid probes for use in hybridization techniques that allow location of luciferase genes in related organisms. The cDNA sequence for a clone that contains a Renilla reniformis luciferase gene is set forth in Figure 1, with the translated cDNA amino acid sequence being set forth in Figure 2. The coding sequence of the clone in Figure 1 begins at nucleotide 10 and continues to a stop codon at nucleotide 944. Figure 3 shows a complete recombinant Renilla luciferase amino acid sequence as produced by an expression system.

The present invention has specifically contemplated each and every possible variation of polynucleotide that could be made by selecting combinations based on the possible codon choices listed in Figure 1 (with the reading frame beginning at position 1 of Figure 1) and in Table 1 (below), and all such variations are to be considered as being specifically disclosed and equivalent to the sequence of Figure 1. Codons are preferably selected to fit the host cell in which the enzyme is being produced. Selection of codons to maximize expression of proteins in a heterologous host is a known technique.

Other DNA molecules that code for such peptides can readily be determined from the list of codons in Table 1 and are likewise contemplated as being equi-

valent to the DNA sequence of Figure 1. In fact, since there is a fixed relationship between DNA codons and amino acids in a peptide, any discussion in this application of a replacement or other change in a peptide is equally applicable to the corresponding DNA sequence or to the DNA molecule, recombinant vector, or transformed microorganism in which the sequence is located (and vice versa).

10

15

20

25

30

35

TABLE 1

GENETIC CODE	
5	
Alanine (Ala, A)	GCA, GCC, GCG, GCT
Arginine (Arg, R)	AGA, AGG, CGA, CGC, CGG, CGT
Asparagine (Asn, N)	AAC, AAT
Aspartic acid (Asp, D)	GAC, GAT
10 Cysteine (Cys, C)	TGC, TGT
Glutamine (Gln, Q)	CAA, CAG
Glutamic acid (Glu, E)	GAA, GAG
Glycine (Gly, G)	GGA, GGC, GGG, GGT
Histidine (His, H)	CAC, CAT
15 Isoleucine (Ile, I)	ATA, ATC, ATT
Leucine (Leu, L)	CTA, CTC, CTG, CTT, TTA, TTG
Lysine (Lys, K)	AAA, AAG
Methionine (Met, M)	ATG
Phenylalanine (Phe, F)	TTC, TTT
20 Proline (Pro, P)	CCA, CCC, CCG, CCT
Serine (Ser, S)	AGC, AGT, TCA, TCC, TCG, TCT
Threonine (Thr, T)	ACA, ACC, ACG, ACT
Tryptophan (Trp, W)	TGG
Tyrosine (Tyr, Y)	TAC, TAT
25 Valine (Val, V)	GTA, GTC, GTG, GTT
Termination signal	TAA, TAG, TGA

Key: Each 3-letter triplet represents a trinucleotide of DNA having a 5' end on the left and a 3' end on the right. The letters stand for the purine or pyrimidine bases forming the nucleotide sequence: A = adenine, G = guanine, C = cytosine, and T = thymine. The RNA code is the same except that U (uracil) replaces T.

In addition to the specific nucleotides listed in Figure 1, DNA (or corresponding RNA) molecules of the invention can have additional nucleotides preceding or following those that are specifically listed. For example, poly A can be added to the 3'-terminal; a short (e.g., fewer than 20 nucleotides) sequence can be added to either terminal to provide a terminal sequence corresponding to a restriction endonuclease site, stop codons can follow the peptide sequence to terminate translation, and the like. Additionally, DNA molecules containing a promoter region or other control region upstream from the gene can be produced. All DNA molecules containing the sequences of the invention will be useful for at least one purpose since all can minimally be fragmented to produce oligonucleotide probes and be used in the isolation or detection of DNA from biological sources.

A number of words used in this specification have specific meanings in addition to their more common meanings. "Renilla luciferase" means the luciferase enzyme isolated from a member of the genus Renilla or an equivalent molecule obtained from any other source or synthetically. By "equivalent" is meant, when referring to two nucleotide sequences, that the two nucleotide sequences in question encode the same sequence of amino acids. When "equivalent" is used in referring to two peptides, it means that the two peptides will have substantially the same amino acid sequence. When "equivalent" refers to a property, the property does not need to be present to the same extent (e.g., two peptides can exhibit different rates of the same type of enzymatic activity), but the properties are preferably substantially the same. "Complementary," when referring to two nucleotide sequences, means that the two sequences are capable of hybridizing, preferably with less than 25%, more preferably with less than 15%, even more preferably

with less than 5%, most preferably with no mismatches between opposed nucleotides. Preferred hybridizing conditions (which are not limited to specific numbers of mismatches) are set forth in the Examples. The term "substantially" varies with the context as understood by those skilled in the relevant art and generally means at least 70%, preferably means at least 80%, more preferably at least 90%, and most preferably at least 95%. The phrase "substantially identical" includes complete identity as well as less than complete identity (e.g., of amino acid sequences or enzymatic activity) as established by the prior definition of "substantially." The term "isolated" as used herein refers to, e.g., a peptide, DNA, or RNA separated from other peptides, DNAs, or RNAs, respectively, and being found in the presence of (if anything) only a solvent, buffer, ion or other component normally present in a biochemical solution of the same. "Isolated" does not encompass either natural materials in their native state or natural materials that have been separated into components (e.g., in an acrylamide gel) but not obtained either as pure substances or as solutions. The phrase "replaced by" or "replacement" as used herein does not necessarily refer to any action that must take place but to the peptide that exists when an indicated "replacement" amino acid is present in the same position as the amino acid indicated to be present in a different formula (e.g., when leucine instead of valine is present at amino acid 11).

Since the DNA sequence of the Renilla luciferase gene has been identified, it is possible to produce a DNA gene entirely by synthetic chemistry, after which the gene can be inserted into any of the many available DNA vectors using known techniques of recombinant DNA technology. Thus, the present invention can be carried out using reagents, plasmids, and microorganisms which are freely available and in the

public domain at the time of filing of this patent application without requiring a deposit of genetic material.

For example, nucleotide sequences greater than 100 bases long can be readily synthesized on an Applied Biosystems Model 380A DNA Synthesizer as evidenced by commercial advertising of the same (e.g., Genetic Engineering News, November/December 1984, p. 3). Such oligonucleotides can readily be spliced using, among others, the technique of preparing overlapping complementary sequences (e.g., 1-100 of coding strand, 0-50 and 51-150 of complementary strand, 101-200 of coding strand, etc.), followed by hybridizing and ligating the strands. Such techniques are well known and are described in detail in, for example, Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publ. Co., Inc., New York (1986). The peptides can then be expressed in a host organism as described herein.

Furthermore, automated equipment is also available that makes direct synthesis of many of the peptides disclosed herein readily available, especially peptide fragments of less than the entire Renilla luciferase enzyme. In the same issue of Genetic Engineering News mentioned above, a commercially available automated peptide synthesizer having a coupling efficiency exceeding 99% is advertised (page 34). Such equipment provides ready access to the peptides of the invention, either by direct synthesis or by synthesis of a series of fragments that can be coupled using other known techniques.

In addition to the specific polypeptide sequence shown in Figures 2 and 3, peptide fragments based on these sequences and fragments and full length sequences representing minor variations thereof will have at least some of the biological activities of luciferase and will therefore be useful in appropriate

circumstances. For example, fragments of the luciferase enzyme sequence can readily be prepared and can be screened for use as luciferin binding site models. Peptide synthesizers can be used to prepare small polypeptide fragments (e.g., less than 100 amino acids) or techniques of genetic engineering can be used to prepare larger fragments. A simple screening procedure that will identify suitable polypeptide fragments consists of attaching a suitable substrate, e.g., a coelenterate luciferin molecule, to an affinity column and capturing peptide fragments that are retained by the bound substrate. Such peptides can also be used (and are indeed more likely to be used) as immunogens for the preparation of antibodies that can be used to screen for the expression of a luciferase by a genetically engineered organism, in which case the bound substrate will be an antibody or similar molecule that binds specifically to Renilla luciferase.

The ability to prepare and select peptide fragments having appropriate binding affinity from a larger protein is well known in the art and is described in a number of publications, including patents. See, for example, U.S. Patent No. 4,629,783, which describes the preparation of immunologically active fragments of viral proteins that bind with the same antibodies as the entire viral protein.

In addition, minor variations of the previously mentioned peptides and DNA molecules are also contemplated as being equivalent to those peptides and DNA molecules that are set forth in more detail, as will be appreciated by those skilled in the art. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (i.e., a conservative replacement) will not have a major effect on the biological activity

of the resulting molecule, especially if the replacement does not involve an amino acid at a binding site or other site of biologic activity. Furthermore, additional amino acids can be present at either of the two termini, or amino acids can be absent from one or both of the termini, as is known in the art.

Whether a change results in a functioning peptide can readily be determined by direct analysis for function in a assay that relies on ability of the modified enzyme (or fragment) to carry out the normal function of the natural luciferase enzyme (or fragment). For example, modified peptides can be tested for ability to catalyze the emission of light from coelenterate luciferin by the same techniques described below for the recombinant Renilla luciferase molecule. Peptides in which more than one replacement has taken place can readily be tested in the same manner. Preferred peptides differ at no more than 12, more preferably no more than 5, amino acids in any contiguous group of 20 amino acids. Substitutions of amino acids, when they occur, are preferably from within standard conservative groups. Standard conservative groups of amino acids are shown in parenthesis using the one-letter amino acid code: non-polar (A,V,L,I,P,M); aromatic (F,T,W); uncharged polar (G,S,T,C,N,Q); acidic (D,E); basic (K,R,H). The aromatic amino acids are sometimes considered to belong to the broader-defined nonpolar (F,W) or uncharged polar (T) groups.

Salts of any of the peptides described herein will naturally occur when such peptides are present in (or isolated from) aqueous solutions of various pHs. All salts of peptides having the indicated biological activity are considered to be within the scope of the present invention. Examples include alkali, alkaline earth, and other metal salts of carboxylic acid residues, acid addition salts (e.g., HCl) of amino resi-

dues, and zwitterions formed by reactions between carboxylic acid and amino residues within the same molecule.

Although genes and corresponding proteins can be prepared by the totally synthetic techniques discussed above, in preferred embodiments of the invention genetic information is obtained from natural sources and identified as described herein. The genetic material is first obtained in the form of a gene library, using any of numerous existing techniques. The first of these is to randomly shear genomic DNA and insert this sheared material into expression vectors. If enough recombinants are generated, there is a good probability of having at least one recombinant in the population which is expressing a fusion protein corresponding to the enzyme of interest.

Another strategy for preparing gene libraries is to make complementary DNA (cDNA) copies of the total mRNA population of the organism and to clone these as recombinant molecules in expression vectors. The expected nature of the organism (i.e., it was expected to have the characteristics of a eucaryote) indicated that introns might be present within the coding region of the desired gene. Although introns do not preclude use of sheared genomic DNA, they increase the number of recombinants which must be screened and make further analyses substantially complicated. Based on this result, use of a cDNA library to obtain Renilla genes is preferred.

Such a library was generated in the laboratory of the inventors and screened for expression of a gene product having luciferase activity. Details of this example are set forth below, including details of the experiments that lead to obtaining the complete sequence of the gene. However, there is no reason to believe that the sequence and specific engineered organism prepared by the inventors is any better than

other clones that can be prepared using the guidance set forth in this specification. In fact, it is likely that expression of Renilla luciferase can be enhanced over that described herein by selection of other
5 expression systems, as discussed in the examples below.

Now that the sequence of Renilla luciferase has been determined, it is no longer necessary to go through these steps to obtain the genetic material of the present invention. The polymerase chain reaction
10 (PCR) technique can now be used to isolate genes from natural sources in a simpler and more direct manner. The PCR technique, including use in diagnosis, is disclosed in U.S. Patent 4,683,202, which is herein incorporated by reference. Since Renilla specimens are
15 readily available from the oceans of the world, and since PCR probes can be prepared using the sequences set forth in this specification, it is possible to obtain any desired segment of the sequences set forth herein using the PCR technique and naturally available
20 sources of Renilla genomic material. A specific example of such a technique for isolating the Renilla luciferase chromosomal gene is described in the examples that follow. The cloned gene can then be inserted into commercial vectors and expressed.

25 Although the techniques set forth above, when used in combination with the knowledge of those skilled in the art of genetic engineering and the previously stated guidelines, will readily enable isolation of the desired gene and its use in recombinant DNA vectors now
30 that sufficient information is provided to locate the gene, other methods which lead to the same result are also known and may be used in the preparation of recombinant DNA vectors of this invention.

Expression of Renilla protein can be enhanced
35 by including multiple copies of the gene in a transformed host; by selecting a vector known to reproduce in the host, thereby producing large quantities of pro-

tein from exogeneous inserted DNA (such as pUC8; ptac12; pIN-III-ompA1, 2, or 3; pOTS; pAS1; or pKK223-3); or by any other known means of enhancing peptide expression.

5 One common variation is the preparation of a polypeptide of the invention in the form of a fused polypeptide. Such peptides are typically prepared by using the promoter region of a gene known to be expressed in a host and inserting nucleotides that encode
10 all or a major portion of the amino acid sequence of the invention into the genetic sequence for the host protein. Examples of such fused proteins include β -galactosidase fused proteins. If desired, the fused peptide can be designed so that a site recognized by a
15 proteolytic enzyme is present at the junction between the two fused proteins. The proteolytic enzyme can then be used to cleave the expressed protein so that the desired luciferase enzyme is available in pure form.

20 In all cases, a Renilla luciferase will be expressed when the DNA sequence is functionally inserted into the vector. By "functionally inserted" is meant in proper reading frame and orientation, as is well understood by those skilled in the art. Typically, a
25 gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein (possibly followed by cleavage) may be used, if desired.

30 In addition to the above general procedures which can be used for preparing recombinant DNA molecules and transformed unicellular organisms in accordance with the practices of this invention, other known techniques and modifications thereof can be used in carrying out the practice of the invention. In partic-
35 ular, techniques relating to genetic engineering have recently undergone explosive growth and development. Many recent U.S. patents disclose plasmids, genetically

engineering microorganisms, and methods of conducting genetic engineering which can be used in the practice of the present invention. For example, U.S. Patent 4,273,875 discloses a plasmid and a process of isolating the same. U.S. Patent 4,304,863 discloses a process for producing bacteria by genetic engineering in which a hybrid plasmid is constructed and used to transform a bacterial host. U.S. Patent 4,419,450 discloses a plasmid useful as a cloning vehicle in recombinant DNA work. U.S. Patent 4,362,867 discloses recombinant cDNA construction methods and hybrid nucleotides produced thereby which are useful in cloning processes. U.S. Patent 4,403,036 discloses genetic reagents for generating plasmids containing multiple copies of DNA segments. U.S. Patent 4,363,877 discloses recombinant DNA transfer vectors. U.S. Patent 4,356,270 discloses a recombinant DNA cloning vehicle and is a particularly useful disclosure for those with limited experience in the area of genetic engineering since it defines many of the terms used in genetic engineering and the basic processes used therein. U.S. Patent 4,336,336 discloses a fused gene and a method of making the same. U.S. Patent 4,349,629 discloses plasmid vectors and the production and use thereof. U.S. Patent 4,332,901 discloses a cloning vector useful in recombinant DNA. Although some of these patents are directed to the production of a particular gene product that is not within the scope of the present invention, the procedures described therein can easily be modified to the practice of the invention described in this specification by those skilled in the art of genetic engineering.

The implications of the present invention are significant in that useful amounts of Renilla luciferase and genetic material of the invention will become available for use in the development of hybridization assays or in any other type of assay utilizing

these materials. Transferring the Renilla luciferase cDNA which has been isolated to other expression vectors will produce constructs which improve the expression of luciferase in E. coli or express the polypeptide in other hosts.

Particularly contemplated is the isolation of genes from related organisms using oligonucleotide probes based on the principal and variant nucleotide sequences disclosed herein. Such probes can be considerably shorter than the entire sequence but should be at least 10, preferably at least 14, nucleotides in length. Intermediate oligonucleotides from 20 to 500, especially 30 to 200, nucleotides in length provide particularly specific and rapid-acting probes. Longer oligonucleotides are also useful, up to the full length of the gene. Both RNA and DNA probes can be used.

In use, the probes are typically labelled in a detectable manner (e.g., with ^{32}P , ^3H , biotin, or avidin) and are incubated with single-stranded DNA or RNA from the organism in which a gene is being sought. Hybridization is detected by means of the label after single-stranded and double-stranded (hybridized) DNA (or DNA/RNA) have been separated (typically using nitrocellulose paper). Hybridization techniques suitable for use with oligonucleotides are well known.

Although probes are normally used with a detectable label that allows easy identification, unlabeled oligonucleotides are also useful, both as precursors of labeled probes and for use in methods that provide for direct detection of double-stranded DNA (or DNA/RNA). Accordingly, the term "oligonucleotide probe" refers to both labeled and unlabeled forms.

In summary, the inventors have reduced the present invention to practice by isolating and sequencing a cDNA clone for Renilla reniformis.

luciferase. The deduced amino acid sequence from this cDNA, beginning at the first methionine residue, predicts a protein of M_r equal to 36 kd, which is the approximate size of native Renilla luciferase. The deduced amino acid sequence also contains within it all six peptide sequences from V-8 protease-digested native Renilla luciferase. Only one mis-match was found between these two sets of amino acid data, a substitution of a tryptophan for a leucine present in the peptide sequence. Comparisons of the native amino acid composition and the predicted recombinant luciferase composition reveal a very high degree of similarity with many identities between specific amino acid residues.

Additionally, expression of luciferase in a genetically engineered organism has been demonstrated. Luciferase activity was found in crude extracts of the original luciferase clone λ RLuc-6. Subcloning the cDNA into the vector pTZ18R increased this activity enough to allow the purification of recombinant luciferase from the pTZRLuc-1 cells. Recombinant luciferase can be purified by a much simplified method from that previously used in the purification of native luciferase. The recombinant luciferase functions identically to native luciferase in all aspects analysed thus far. Like native, recombinant luciferase has an emission spectrum with a λ_{max} at 480 nm and a shoulder at 400 nm. The absorption spectrum of recombinant luciferase is also identical to that of native. Additionally, both native and recombinant luciferase are very stable at 37°C for several hours as well as having significant stability at 45°C. Using the specific activity determined for native luciferase, protein determinations made based on light emission correlate very well with A_{280} and Lowry protein determinations, suggesting that the specific activity of recombinant luciferase is similar to, if

not the same as, that of native luciferase. Finally, amino-terminus amino acid sequence analysis of recombinant luciferase shows an identical sequence to that of the cDNA-predicted amino acid sequence from residues 2 through 18. A significant amount of the recombinant protein is blocked at the amino terminus, probably by N-formyl methionine, which accounts for the inability to determine the amino acid at residue 1.

The invention now being generally described, the same will be better understood by reference to the following examples which are provided for purposes of illustration only and are not to be considered limiting of the invention unless so specified.

EXAMPLES

Assay for Luciferase Activity

Crude supernatants or pure recombinant luciferase samples {10 to 100 μ l} were added to 1 ml of luciferase assay buffer {0.5M NaCl, 0.1M KPO₄ pH 7.6, 1mM EDTA, 0.02% BSA, and 0.004% NaN₃} and vortexed in 12 x 75 mm test tube. Synthetic benzyl luciferin {10 μ l of a 2.5 nmol/ μ l stock} was added to the reaction to give a final concentration of 2.5×10^{-8} M, and the mixture was vortexed rigorously for 4-5 sec. The tube was placed immediately in a Turner Model TD-20e luminometer and peak light emission was determined and converted to photons using a ⁶³Ni radioactive light emission calibration standard.

RNA Isolation and cDNA Synthesis

Live Renilla reniformis were collected by bottom trawling in shallow waters off Sapelo Island in the state of Georgia at the University of Georgia Marine Institute. The animals were washed thoroughly in fresh seawater, quick frozen in liquid nitrogen, and stored at -80°C. Frozen Renilla were crushed to a fine

powder under liquid nitrogen with a mortar and pestle. The powdered tissue was then homogenized with a Waring blender in 4 M guanidine thiocyanate, and total RNA was isolated as described in Chirgwin et al., Biochemistry (1970) 18:5294-5299. Total RNA was then passed over an oligo-dT cellulose column to obtain polyadenylated RNA which was stored as an ethanol precipitate at -20°C. Single and double stranded cDNA were synthesized from poly A⁺ RNA by modification of the Gubler and Hoffman method, Gubler et al., Gene (1983) 25:263-269, as described below. Following T-4 polymerase blunting and methylation of the cDNAs, synthetic EcoRI linkers were blunt-end ligated. After digestion with EcoRI, the excess linkers were separated from the cDNAs by low-melt agarose gel electrophoresis. Only cDNA's greater than about 650 bp in length were isolated from the low melt gel.

Construction and Screening of the λ gt11 Library

Purified cDNA's were ligated into EcoRI-digested λ gt11. The DNA was then packaged using λ phage extracts (Gigapack Plus Kit, Strategene). Several fractions of the packaged library were titered in Y1088 cells; these fractions ranged from 71% to 81% recombinant phage as determined by the lack of IPTG-inducible β -galactosidase activity. The total number of recombinant phage was equal to 2.1×10^6 pfu (plaque forming units). The primary library was then amplified in Y1088 cells and stored in 7% DMSO at -80°C. The titer of the amplified library was 2.5×10^7 pfu/ml and was approximately 65% recombinant.

Two 17-base oligonucleotide probes were synthesized based on amino acid sequence data from isolated peptides derived from V-8 protease digested, native Renilla luciferase. Shown in Figure 4 are the amino acid sequences of the seven V-8 luciferase peptides. The amino acid sequences with the lowest

codon redundancy were selected for synthesis of luciferase oligonucleotide Probe #1 and Probe #2, which are shown highlighted with their derived nucleotide sequences (lower portion of Figure 4). Probe #1 was derived from peptide 7 and contained 32 redundancies, while Probe #2, derived from peptide 1, contained 64 redundancies. The probes were end-labeled with T-4 polynucleotide kinase to high specific activity ($4-9 \times 10^8$ cpm/ μ g). Y1088 cells were infected with enough phage to give 3×10^4 pfu/plate. The infected cells were plated in 6 ml of top agarose onto 150 mm diameter Luria plates containing 50 μ g/ml ampicillin. After overnight incubation at 37°C, the plates were chilled at 4°C before performing plaque lifts. To eliminate false positive signals, duplicate nitrocellulose filter plaque replicas were prepared from each master plate. Filters were processed by base treatment followed by neutralization in Tris buffer.

The filters were air dried and baked at 80°C in vacuo. Prehybridization was for at least 6 hours at 37°C in 6X SSC, 50 mM Sodium Phosphate (pH 6.8), 5X Denhardt's, and 100 μ g/ml denatured Herring sperm DNA. Hybridization was overnight at 37°C in prehybridization solution with the addition of dextran sulfate to a final concentration of 10%. The labeled probes were added to the hybridization solution at $1-2 \times 10^6$ cpm/ml.

Filter washes were done in the presence of tetramethylammonium chloride under the conditions described for a 17-base oligonucleotide in Wood et al., Proc. Nat. Acad. Sci. USA (1985) 82:1585-1588. Each duplicate filter was hybridized to both probes in the first round of screening; in subsequent rounds, the duplicate filters were hybridized to either Probe #1 or Probe #2. All cDNA clones were plaque purified after three or four rounds of screening; phage DNA was isolated from each clone on glycerol step gradients as

described in Grossberger, D., Nuc. Acid. Res. (1987) 15(16):6737.

DNA Sequence Analysis

- 5 All DNA sequence analysis was done in the M13
vectors mp18 and mp19. Single stranded templates were
prepared and dideoxynucleotide sequencing was performed
using a Sequenase DNA Sequencing Kit obtained from
United States Biochemical Corporation. Sequencing
10 reactions were primed using either the M13 universal
primer, a primer which hybridized to extraneous λ gt11
DNA present in some constructs, or the oligonucleotide
probes. Sequence data obtained from both ends of the
cDNA was analyzed for six base restriction enzyme sites
15 which were used to generate sequencing subclones
(Figure 5). In this way, the entire 1.2 kb cDNA was
sequenced on both strands (lower portion of Figure
5). All DNA sequences and translated protein sequences
were assembled and analyzed using MicroGenie Sequence
20 Software purchased from Beckman.

Expression in E. coli

- The initial luciferase cDNA clone, λ RLuc-6,
was in the expression vector λ gt11. The clone was
25 amplified in Y1088 cells and the high titer stock was
used to make lysogens in Y1089. The λ RLuc-6 lysogen
was then grown in Luria broth plus ampicillin (50
 μ g/ml) at 37°C. The cells were pelleted, resuspended
in TE buffer, and lysed with lysozyme (2 mg/ml). The
30 cell debris was then pelleted and the supernatant was
assayed for luciferase activity. The 2.2kbp λ RLuc-6
insert which included 1 kb of λ gt11 lacZ DNA attached
to the 3' end was isolated on a low-melt gel and
subcloned into the EcoRI/SstI sites of pTZ18R
35 (Pharmacia). This construct, pTZRLuc-1, was used in
the expression and purification of recombinant Renilla
luciferase.

Electrophoretic and Western Analysis

Recombinant luciferase samples were characterized on Commassie-stained SDS-PAGE gels. For Western analysis, the gels were run and transferred to nitrocellulose filters at 30 mA in transfer buffer as described in Burnett, N.W., Analytical Biochemistry (1981) 112:195-203. The filters were blocked with 3% BSA and incubated with a 1/1000 dilution of polyclonal rabbit-anti-luciferase antibodies. Next, the filter was washed in TBS and incubated with a 1/2500 dilution of the secondary antibody, goat-anti-rabbit IgG conjugated to horseradish peroxidase (Bio-Rad). Finally, the filter was washed in TBS and developed with HRP-Color Developing reagent (Bio-Rad).

Emission Spectra

Crude samples of pTZLuc-1 cells were prepared as described previously in this text. The sample was added to 1 ml of luciferase assay buffer; 1 μ l luciferin (917 nmol/ μ l) was added at 1-2 minute intervals to maintain the signal. The bioluminescence emission spectra were obtained and corrected using an on-line computerized SPEX fluorimeter. Multiple spectra were scan averaged to give the final spectrum which was measured from 675 nm to 375 nm.

Protein Purification

Purification of recombinant Renilla luciferase from pTZRLuc-1 E. coli extracts was accomplished in three chromatographic steps. Recombinant luciferase was purified from pTZRLuc-1 cells as follows: pTZRLuc-1 cells were grown in 20L Luria broth at 37°C at an OD₆₀₀=0.6 at which time IPTG was added to a final concentration of 0.5 mM; cells continued to grow overnight at 30°C. The cells were harvested by centrifugation, washed in TE, resuspended in 5 ml of 10

5 mM EDTA (pH 8) per gram of cells, and frozen at -20°C. In a typical purification, 15 to 30 grams of cells were thawed. Lysozyme was added to a final concentration of 4 to 6 mg/ml, and the cells were held on ice for 45 minutes. DNase 1 (10 to 20 mg) was added to the lysate which was sonicated on ice with 1 minute bursts from a Branson Cell Disrupter until 90% of the cells were lysed as evidenced by microscopic examination.

10 The crude material was clarified by centrifugation at 48 X g for 30 minutes and loaded onto the first column. The extract was first run on a DEAE-Cellulose ion-exchange column followed by a G-100 Sephadex gel filtration column and then a Benzoic Acid-Sepharose affinity column. The G-100 column was run in 1X Renilla Standard Buffer (1.5 mM Tris, 1.0 mM EDTA pH 7.8). The other columns were run in 1X buffer and were eluted in 10X buffer (DEAE) or Sodium Benzoate in 10X buffer (Benzoic Acid-Sepharose). The first Benzoic

15 Acid column was eluted with 0.1 M sodium benzoate pulse. The second Benzoic Acid column was eluted with a 0 to 0.5 M sodium benzoate gradient. Protein determinations were made by A_{280} measurements using the extinction coefficient of native luciferase ($\epsilon_{280\text{nm}}^{0.1\%} = 2.1$), by light emission using the specific activity of naive luciferase ($1.8 \times 10^{15} \text{ hv sec}^{-1} \text{ mg}^{-1}$), or by Bradford assays as described in Bradford, M., Analytical Biochemistry (1976) 72: 248. Absorption spectra were measured and collected on a Varian Model

25 DMS-100 spectrophotometer.

30

Isolation and Analysis of λ RLuc-6

The primary screen of 1×10^6 recombinant phage resulted in the isolation of nine clones which gave identical autoradiographic signals on both replica filters. Of the nine original positives, only five gave signals on the second screening, and only one of

35

the five hybridized to both probes. The other four hybridized only to Probe #2, which has the greatest sequence redundancy. Restriction enzyme analysis of the five clones revealed that λ RLuc-3 and λ RLuc-8 were identical and contained a 1.16 kb insert. λ RLuc 2, 5, and 6 had insert sizes of 0.8, 2.34 and 1.2 kbp respectively. Only the λ RLuc-3 and λ RLuc-8 inserts could be excised from the EcoRI cloning site by EcoRI digestion. The other three inserts had apparently lost one EcoRI linker site; these had to be cut with EcoRI and SstI. Thus, each of these cDNAs contained 1 kb of λ gt11 DNA attached at one end. Since only λ RLuc-6 hybridized to both oligonucleotide probes and contained a cDNA of the size necessary to code for an approximately 36 kd protein, it was chosen for DNA sequence analysis.

The 2.2kb EcoRI/SstI fragment, which contained 1 kb of λ gt11 lac Z DNA, was subcloned into M13 and mp18 and mp19 and both strands of the 1.2 kb cDNA were completely sequenced. The entire cDNA sequence is 1196 bp, excluding the EcoRI linker (Figure 1). Structurally, it contains a putative initiation codon beginning at nucleotide 10, a stop codon at nucleotide 944, a polyadenylation consensus sequence at nucleotide 1170, and a short polyadenylated tail of seven nucleotides (Figure 1). Also shown underlined in Figure 1 are the two oligonucleotide hybridization sites located at nucleotides 537-554 (Probe #1) and nucleotides 820-836 (Probe #2). The loss of the EcoRI site at the 3' end of the cDNA was confirmed by the sequence analysis.

The cDNA does not contain a stop codon in frame with and upstream from the first initiation codon as an indication that the protein coding region is full length. However, the coding region directs the recombinant synthesis of fully active Renilla luciferase, as discussed below. Translating the cDNA

sequence into an amino acid sequence gave conclusive evidence that the λ RLuc-6 cDNA was a Renilla luciferase cDNA. The translated cDNA sequence contains an open reading frame of 314 amino acids (Figure 2). The first
5 methionine is preceded by three amino acids which may or may not be part of the native protein sequence. If the in vivo translation begins at the first methionine, an open reading frame of 311 amino acids results which codes for a protein of molecular weight (M_r) ~36 Kd.
10 The M_r of native Renilla luciferase has been measured by various methods with values ranging from 33 Kd to 38 Kd. Comparing the amino acid composition of this translated amino acid sequence with that of the previously published native luciferase composition
15 shows a very close homology with many identities between the two (Table 2).

20

25

30

35

TABLE 2
Amino Acid Composition of Native and
Recombinant Renilla reniformis Luciferase

Amino Acids	Residues (Native)	Residues (Recombinant)
Lysine	26	27
Histidine	10	10
Arginine	12	13
Aspartate*	31	30
Threonine	9	6
Serine	20	19
Glutamate**	36	37
Proline	17	18
Glycine	19	17
Alanine	19	19
Valine	23	23
Methionine	7	9
Isoleucine	20	21
Leucine	23	22
Tyrosine	12	13
Phenylalanine	15	15
Tryptophan	7	8
Cysteine	3	3

*Aspartate + Asparagine

**Gltamate + Glutamine

Native luciferase composition data taken from Matthews
et al., Biochemistry (1977) 16: 85-91.

Further evidence that the cDNA does code for
luciferase can be seen by comparing the V-8 protease
peptide sequences with the translated cDNA sequence
(Figure 3). All V-8 peptides were located on the
carboxyl-terminal half of the translated coding region
beginning at residue 161; several overlapped with one
another. Except at one residue, 219, where the cDNA
sequence predicts a tryptophan but peptide 6 sequence
indicates a leucine at the same position, all peptides
matched exactly to regions of the translated
sequence. Bunching of the peptides at one end of the

protein sequence may be due to the amino-terminal half of the native protein being folded in such a way as to be inaccessible to V-8 protease.

5 Expression of Recombinant Luciferase in *E. coli*

 The original λ RLuc 6 lysogen showed low levels of luciferase activity as determined by light emission. IPTG induction of λ RLuc-6 lysogens led to an approximate 50% decrease in activity. This result was later explained when DNA sequence data revealed that the 3' end of the cDNA was adjacent to the lac Z sequence in λ gt11. Therefore, under conditions of IPTG induction, transcription was being forced in the wrong direction with respect to the luciferase cDNA orientation. Presumably, the non-induced luciferase expression in this construct was due to promoter activity from the left end of λ gt11 at a site which we have not determined.

 The construct pTZRLuc-1 was made to simplify the isolation of DNA fragments for use as probes in Southern and Northern analysis (Figure 6). *E. coli* cells harboring this plasmid are referred to as pTZRLuc-1 cells. Similar to λ gt11, the pTZ series "phagemids" contain a polylinker site adjacent to the lac Z' gene. Expressed genes in this vector could potentially be expressed containing the first 10 to 15 amino acids of β -galactosidase fused to the cDNA translation product. Analysis of pTZRLuc-1 cell supernatants for light emission showed that, relative to λ RLuc-6, high levels of luciferase activity were present. Furthermore, induction of pTZRLuc-1 cells with 0.5 mM IPTG led to an increase in luciferase activity of ~ 5-8 fold in crude extracts.

 The bioluminescence emission spectrum from these crude supernatants was identical to the previously published bioluminescence emission spectrum for native *Renilla* luciferase. The wavelength

distribution of light emission is essentially identical to that reported earlier. The spectrum had an emission maximum (λ_{max}) at 480 nm with a slight shoulder at 400 nm, which presumably corresponded to the luciferase-oxygenyluciferin complex neutral species excited state.

The pTZRLuc-1 crude supernatants were further characterized by SDS-PAGE. The Coomassie-stained gel contained numerous bands, one of which ran in the vicinity of native luciferase. To confirm that this band was recombinant luciferase, Western analysis was performed using rabbit polyclonal antibodies raised against native Renilla luciferase. The developed Western showed one band that migrated at the same position as native luciferase. No other products indicative of β -galactosidase-luciferase fusion polypeptide were apparent, suggesting that either any putative fusion protein is in too low a concentration to be detected or, more likely, that no fusion protein is made. Though it has not been confirmed by DNA sequence analysis, any pTZRLuc-1 translation products initiating at the β -galactosidase ATG start codon within the first three codons immediately adjacent to the first cDNA start codon may explain why we see IPTG induction of luciferase activity without production of a fusion product.

IPTG induction of recombinant luciferase indicates that its transcription is directed by the lac Z promoter. Since the only candidate ribosome binding site (RBS) is probably positioned too far (18 nucleotides) from the luciferase ATG to be functional, we suspect that a β -galactosidase peptide is being translated to the stop codon immediately adjacent to the luciferase ATG. The translation of a β -galactosidase peptide may facilitate ribosome reinitiation at the luciferase ATG codon (Figure 7). This event could occur if the dinucleotide AG was acting as a RBS for the luciferase cDNA. In this way

an IPTG inducible, non-fusion luciferase polypeptide could be synthesized. Given the success of recombinant luciferase expression using the pTZ18 vector, which was designed as a multi-purpose in vitro transcription vector rather than an expression vector, it is obvious that other clones can be developed which express luciferase at levels greater than those which we currently obtain.

10 Purification of Recombinant Renilla Luciferase

Using the specific activity for native luciferase, we made calculations for the amount of luciferase present in IPTG induced, pTZRLuc-1 crude supernatants and determined that the amount of recombinant luciferase being produced was sufficient to attempt initial purification on a small scale.

In IPTG induced pTZRLuc-1 cells, recombinant luciferase represents approximately 12-14% of the total protein in the clarified crude supernatant. Although significant losses of recombinant luciferase were suffered in this initial purification, the amount of starting material and time involved made the loss seem insignificant when compared to the purification of native luciferase. The purification scheme for the recombinant Renilla luciferase is shown in Figure 8; the purification is summarized in Table 3. SDS-PAGE analysis of the purification steps shows increasing amounts of recombinant luciferase with respect to contaminating protein. The Benzoic Acid-Sepharose luciferase is approximately 99% pure as evidenced by a single band of M_r equal to 34 Kd. Very slight contamination was noticeable on the Coomassie stained gel if more than 20 μ g of protein were loaded.

35

important feature for the utility of recombinant luciferase in diagnostic applications, many of which require incubation at physiological temperatures.

Purification of recombinant Renilla luciferase
5 has allowed us to determine its amino-terminal sequence. The amino acid sequence of the first 18 residues was determined by Edman degradation. The amino acid peak heights of the sequence data indicated that far less protein was actually being sequenced than
10 was initially protein synthesis, it may be that a large percentage of recombinant luciferase is N-formylated at the initiating methionine and thus blocked to the Edman reaction. In spite of this apparent amino-terminal block, enough unblocked species were available that we
15 were able to obtain sequence for the first 18 residues of recombinant luciferase. The amino acid sequence is identical to the translated cDNA sequence from residues 2 through 18 (Figure 7). On cycle 1 of the amino acid sequencing run, we were not able to confirm the
20 presence of a methionine at the first residue as predicted by the cDNA sequence. However, the fact that the two sets of amino acid data are identical from amino acid residue 2 (Threonine) to residue 18 (Proline) strongly supports our assertion that the
25 first predicted methionine in our sequence is acting as the initiation codon in the pTZRLuc-1 construct.

All publications and patent applications mentioned in this specification are herein incorporated
30 by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art
35 that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

important feature for the utility of recombinant luciferase in diagnostic applications, many of which require incubation at physiological temperatures.

Purification of recombinant Renilla luciferase has allowed us to determine its amino-terminal sequence. The amino acid sequence of the first 18 residues was determined by Edman degradation. The amino acid peak heights of the sequence data indicated that far less protein was actually being sequenced than was initially protein synthesis, it may be that a large percentage of recombinant luciferase is N-formylated at the initiating methionine and thus blocked to the Edman reaction. In spite of this apparent amino-terminal block, enough unblocked species were available that we were able to obtain sequence for the first 18 residues of recombinant luciferase. The amino acid sequence is identical to the translated cDNA sequence from residues 2 through 18 (Figure 7). On cycle 1 of the amino acid sequencing run, we were not able to confirm the presence of a methionine at the first residue as predicted by the cDNA sequence. However, the fact that the two sets of amino acid data are identical from amino acid residue 2 (Threonine) to residue 18 (Proline) strongly supports our assertion that the first predicted methionine in our sequence is acting as the initiation codon in the pTZRLuc-1 construct.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated DNA or RNA molecule, which
comprises a nucleotide sequence coding for Renilla
5 luciferase.

2. The molecule of Claim 1, wherein said molecule
comprises the luciferase coding sequence:

10 AGCTTAAAGATGACTTCGAAAGTTTATGATCCAGAACAAAGGAAACGGAT
GATAACTGGTCCGCAGTGGTGGGCCAGATGTAAACAAATGAATGTTCTTG
ATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAATGCTGTT
ATTTTTTTACATGGTAACGCGGCCTCTTCTTATTTATGGCGACATGTTGT
GCCACATATTGAGCCAGTAGCGCGGTGTATTATACCAGATCTTATTGGTA
15 TGGGCAAATCAGGCAAATCTGGTAATGGTTCTTATAGGTTACTTGATCAT
TACAAATATCTTACTGCATGGTTGAACTTCTTAATTTACCAAAGAAGAT
CATTTTTGTCGGCCATGATTGGGGTGCTTGGTTCATTTCATTATAGCT
ATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTA
GATGTGATTGAATCATGGGATGAATGGCCTGATATTGAAGAAGATATTGC
20 GTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTGGAGAATAACTTCT
TCGTGGAACCATGTTGCCATCAAAAATCATGAGAAAGTTAGAACCAGAA
GAATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTGC
TCCAACATTATCATGGCCTCGTGAAATCCCGTTAGTAAAAGGTGGTAAAC
CTGACGTTGTACAAATTGTTAGGAATTATAATGCTTATCTACGTGCAAGT
25 GATGATTTACCAAAAATGTTTATTGAATCGGATCCAGGATTCTTTTCCAA
TGCTATTGTTGAAGGCGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAG
TAAAAGGTCTTCATTTTTCGCAAGAAGATGCACCTGATGAAATGGGAAAA
TATATCAAATCGTTCGTTGAGCGAGTTCTCAAAAATGAACAA

30 or an equivalent DNA or RNA sequence.

3. The molecule of Claim 2, wherein said molecule
is DNA.

35 4. The molecule of Claim 3, wherein said molecule
contains said luciferase sequence.

5. The molecule of Claim 2, wherein said molecule is RNA and contains a sequence equivalent to said luciferase sequence.

5

6. The molecule of Claim 1, wherein said sequence is preceded by a functional promoter sequence 5' to said sequence.

10

7. The molecule of Claim 6, wherein at least one copy of said sequence is present in a recombinant DNA or RNA vector.

15

8. A genetically engineered microorganism, wherein said microorganism comprises the vector of Claim 7.

20

9. The microorganism of Claim 8, wherein said microorganism is an E. coli strain.

10. An isolated oligonucleotide, comprising at least 10 consecutive nucleotides selected from nucleotide sequence:

25 AGCTTAAAGATGACTTCGAAAGTTTATGATCCAGAACAAAGGAAACGGAT
GATAACTGGTCGCAGTGGTGGGCCAGATGTAAACAAATGAATGTTCTTG
ATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAAATGCTGTT
GCCACATATTGAGCCAGTAGCGCGGTGTATTATACCAGATCTTATTGGTA
30 TGGGCAAATCAGGCAAATCTGGTAATGGTTCTTATAGGTTACTTGATCAT
TACAAATATCTTACTGCATGGTTTGAACCTCTTAATTTACCAAAGAAGAT
CATTTTTGTGCGCCATGATTGGGGTGCTTGTTTGGCATTTCATTATAGCT
ATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTA
GATGTGATTGAATCATGGGATGAATGGCCTGATATTGAAGAAGATATTGC
35 GTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTGGAGAATAACTTCT
TCGTGGAAACCATGTTGCCATCAAAAATCATGAGAAAGTTAGAACCAGAA
GAATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTGC
TCCAACATTATCATGGCCTCGTGAAATCCCGTTAGTAAAAGGTGGTAAAC

CTGACGTTGTACAAATTGTTAGGAATTATAATGCTTATCTACGTGCAAGT
GATGATTTACCAAAAATGTTTATTGAATCGGATCCAGGATTCTTTTCCAA
TGCTATTGTTGAAGGCGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAG
TAAAAGGTCTTCATTTTTTCGCAAGAAGATGCACCTGATGAAATGGGAAAA
5 TATATCAAAATCGTTTCGTTGAGCGAGTTCTCAAAAATGAACAATAATTACT
TTGGTTTTTTATTTACATTTTCCCGGGTTTAATAATATAAATGTCATT
TCAACAATTTTATTTTAACTGAATATTTACAGGGAACATTCATATATGT
TGATTAATTTAGCTCGAACTTTACTCTGTTCATATCATTTTGAATATTAC
CTCTTTCAATGAACTTTATAAACAGTGGTTCAATTAATTAATATATATT
10 ATAATTACATTTGTTATGTAATAAACTCGGTTTTATTATAA,

complementary DNA sequences, and equivalent or
complementary RNA sequences.

15 11. The oligonucleotide of Claim 10, wherein said
oligonucleotide is labeled with a detectable tag.

12. The oligonucleotide of Claim 10, wherein said
oligonucleotide comprises at least 14 consecutive
20 nucleotides.

13. A method of identifying genetic material
encoding a coelenterate luciferase gene, comprising;
isolating genetic material from a coelenterate
25 organism to form a sample of genetic material,
contacting said sample with an oligonucleotide
of Claim 10 under hybridizing conditions, and
detecting formation of a duplex comprising
said oligonucleotide and DNA or RNA present in said
30 sample.

14. The method of Claim 13, where said method
comprises a polymerase chain reaction.

35 15. A genetically engineered peptide encoded by a
nucleotide sequence of Claim 1.

16. The peptide of Claim 15, wherein said peptide is non-glycosylated.

17. A peptide comprising the amino acid sequence of Figure 3 or a fragment of said sequence comprising at least 5 consecutive amino acid residues in which the fragment is immunologically reactive with an antibody that specifically binds Renilla luciferase, wherein said peptide is free from other Renilla peptides.

10

15

20

25

30

35

1 / 8

FIG. 1

10	20	30	40	50	60
AGCTTAAAGA	TGACTTCGAA	AGTTTATGAT	CCAGAACAAA	GGAAACGGAT	GATAACTGGT
70	80	90	100	110	120
CCGCAGTGGT	GGGCCAGATG	TAAACAAATG	AATGTTCTTG	ATTCATTTAT	TAATTATTAT
130	140	150	160	170	180
GATTTCAGAAA	AACATGCAGA	AAATGCTGTT	ATTTTTTTAC	ATGGTAACGC	GGCCTCTTCT
190	200	210	220	230	240
TATTTATGGC	GACATGTTGT	GCCACATATT	GAGCCAGTAG	CGCGGTGTAT	TATACCAGAT
250	260	270	280	290	300
CTTATTGGTA	TGGGCAAATC	AGGCAAATCT	GGTAATGGTT	CTTATAGGTT	ACTTGATCAT
310	320	330	340	350	360
TACAAATATC	TTACTGCATG	GTTTGAACCT	CTTAATTTAC	CAAAGAAGAT	CATTTTTGTC
370	380	390	400	410	420
GGCCATGATT	GGGGTGCTTG	TTTGGCATT	CATTATAGCT	ATGAGCATCA	AGATAAGATC
430	440	450	460	470	480
AAAGCAATAG	TTCACGCTGA	AAGTGTAGTA	GATGTGATTG	AATCATGGGA	TGAATGGCCT
490	500	510	520	530	540
GATATTGGAAG	AAGATATTGC	GTTGATCAAA	TCTGAAGAGG	GAGAAAAAAT	GGTTTTGGAG
550	560	570	580	590	600
<u>AATAACTTCT</u>	<u>TCGTGGAAAC</u>	CATGTTGCCA	TCAAAAATCA	TGAGAAAGTT	AGAACCAGAA
610	620	630	640	650	660
GAATTTGCAG	CATATCTTGA	ACCATTCAAA	GAGAAAGGTG	AAGTTCGTCG	TCCAACATTA
670	680	690	700	710	720
TCATGGCCTC	GTGAAATCCC	GTTAGTAAAA	GGTGGTAAAC	CTGACGTTGT	ACAAATTGTT
730	740	750	760	770	780
AGGAATTATA	ATGCTTATCT	ACGTGCAAGT	GATGATTTAC	CAAAAATGTT	TATTGAATCG
790	800	810	820	830	840
GATCCAGGAT	TCTTTTCCAA	TGCTATTGTT	GAAAGGCGCA	<u>AGAAGTTTCC</u>	<u>TAATACTGAA</u>
850	860	870	880	890	900
TTTGTCAAAG	TAAAAGGTCT	TCATTTTTCG	CAAGAAGATG	CACCTGATGA	AATGGGAAAA
910	920	930	940	950	960
TATATCAAAT	CGTTCGTTGA	GCGAGTTCTC	AAAAATGAAC	AATAATTACT	TTGGTTTTTT
970	980	990	1000	1010	1020
ATTTACATTT	TTCCCGGGTT	TAATAATATA	AATGTCATTT	TCAACAATTT	TATTTTAACT
1030	1040	1050	1060	1070	1080
GAATATTTC	CAGGGAACAT	TCATATATGT	TGATTAATTT	AGCTCGAACT	TTACTCTGTC
1090	1100	1110	1120	1130	1140
ATATCATTTT	GGAATATTAC	CTCTTCAAT	GAAACTTTAT	AAACAGTGGT	TCAATTAATT
1150	1160	1170	1180	1190	
AATATATATT	ATAATTACAT	TTGTTATGTA	ATAAACTCGG	TTTTATTATA	AAAAAA

SUBSTITUTE SHEET

2 / 8

FIG. 2

10
 Ser Leu Lys Met Thr Ser Lys Val Tyr Asp Pro Glu Gln Arg Lys Arg Met Ile Thr Gly 20
 30
 Pro Gln Trp Trp Ala Arg Cys Lys Gln Met Asn Val Leu Asp Ser Phe Ile Asn Tyr Tyr 40
 50
 Asp Ser Glu Lys His Ala Glu Asn Ala Val Ile Phe Leu His Gly Asn Ala Ala Ser Ser 60
 70
 Tyr Leu Trp Arg His Val Val Pro His Ile Glu Pro Val Ala Arg Cys Ile Ile Pro Asp 80
 90
 Leu Ile Gly Met Gly Lys Ser Gly Lys Ser Gly Asn Gly Ser Tyr Arg Leu Leu Asp His 100
 110
 Tyr Lys Tyr Leu Thr Ala Trp Phe Glu Leu Leu Asn Leu Pro Lys Lys Ile Ile Phe Val 120
 130
 Gly His Asp Trp Gly Ala Cys Leu Ala Phe His Tyr Ser Tyr Glu His Gln Asp Lys Ile 140
 150
 Lys Ala Ile Val His Ala Glu Ser Val Val Asp Val Ile Glu Ser Trp Asp Glu Trp Pro 160
 170
 Asp Ile Glu Glu Asp Ile Ala Leu Ile Lys Ser Glu Glu Gly Glu Lys Met Val Leu Glu 180
 190
 Asn Asn Phe Phe Val Glu Thr Met Leu Pro Ser Lys Ile Met Arg Lys Leu Glu Pro Glu 200
 210
 Glu Phe Ala Ala Tyr Leu Glu Pro Phe Lys Glu Lys Gly Glu Val Arg Arg Pro Thr Leu 220
 230
 Ser Trp Pro Arg Glu Ile Pro Leu Val Lys Gly Gly Lys Pro Asp Val Val Gln Ile Val 240
 250
 Arg Asn Tyr Asn Ala Tyr Leu Arg Ala Ser Asp Asp Leu Pro Lys Met Phe Ile Glu Ser 260
 270
 Asp Pro Gly Phe Phe Ser Asn Ala Ile Val Glu Gly Ala Lys Lys Phe Pro Asn Thr Glu 280
 290
 Phe Val Lys Val Lys Gly Leu His Phe Ser Gln Glu Asp Ala Pro Asp Glu Met Gly Lys 300
 310
 Tyr Ile Lys Ser Phe Val Glu Arg Val Leu Lys Asn Glu Gln

SUBSTITUTE SHEET

FIG. 3A

1 MET THR SER LYS VAL TYR ASP PRO GLU GLN ARG LYS ARG MET ILE THR GLY PRO GLN TRP 20
 21
 41 TRP ALA ARG CYS LYS GLN MET ASN VAL LEU ASP SER PHE ILE ASN TYR TYR ASP SER GLU 40
 61 LYS HIS ALA GLU ASN ALA VAL ILE PHE LEU HIS GLY ASN ALA ALA SER SER TYR LEU TRP 60
 81 ARG HIS VAL VAL PRO HIS ILE GLU PRO VAL ALA ARG CYS ILE ILE PRO ASP LEU ILE GLY 80
 101 MET GLY LYS SER GLY LYS SER GLY ASN GLY SER TYR ARG LEU LEU ASP HIS TYR LYS TYR 100
 121 LEU THR ALA TRP PHE GLU LEU LEU ASN LEU PRO LYS LYS ILE ILE PHE VAL GLY HIS ASP 120
 141 TRP GLY ALA CYS LEU ALA PHE HIS TYR SER TYR GLU HIS GLN ASP LYS ILE LYS ALA ILE 140
 161 VAL HIS ALA GLU SER VAL VAL ASP VAL ILE GLU SER TRP ASP GLU TRP PRO ASP ILE GLU 160

161

GLN ASP ILE ALA ILEU ILE LYS SER GLU GLU GLY GLU LYS MET VAL LEU GLN ASN ASN PHE

180

181

PHE VAL GLN THR MET LEU PRO SER LYS ILE MET ARG LYS LEU GLU PRO GLU GLU PHE ALA

200

201

ALA TYR LEU GLU PRO PHE LYS GLN LYS GLY GLN VAL ARG ARG PRO THR ILE SER TRP PRO

220

221

ARG GLN ILE PRO ILEU VAL LYS GLY GLY LYS PRO ASP VAL VAL GLN ILE VAL ARG ASN TYR

240

241

ASN ALA TYR LEU ARG ALA SER ASP ASP LEU PRO LYS MET PHE ILE GLN SER ASP PRO GLY

260

261

PHE PHE SER ASN ALA ILE VAL GLN GLY ALA LYS LYS PHE PRO ASN THR GLU PHE VAL LYS

280



281



VAL LYS GLY LEU HIS PHE SER GLN GLU ASP ALA PRO ASP GLU MET GLY LYS TYR ILE LYS

300

301

SER PHE VAL GLN ARG VAL ILE LYS ASN GLN GLN

Peptide 1:  Peptide 4: 

Peptide 2:  Peptide 5: 




Peptide 3:  Peptide 6: 

FIG.3B

Peptide 7: 

5 / 8

- 1) GLU-GLY-ALA LYS-LYS-PHE-PRO-ASN-THR-GLU
- 2) GLU-ARG-VAL-LEU-LYS-ASN-GLU
- 3) GLU-GLY-GLU-LYS-MET-VAL-LEU-GLU
- 4) GLU-ASP-ILE-ALA-LEU-ILE-LYS-SER-GLU
- 5) GLU-SER-ASP-PRO-GLY-PHE-PHE-SER-ASN-ILE-VAL-GLU
- 6) GLU-LYS-GLY-GLU-VAL-ARG-ARG-PRO-THR-LEU-SER-LEU-PRO-ARG-
GLU-ILE-PRO-LEU-VAL-LYS-GLY
- 7) GLU-ASN-ASN-PHE-PHE-VAL-GLU

GLU-ASN-ASN-PHE-PHE-VAL

Luciferase Probe #1: GAA-AAT-AAT-TTT-TTT-GT
(32 degeneracies) G C C C C

LYS-LYS-PHE-PRO-ASN-THR

Luciferase Probe #2: AAA-AAA-TTT-CCT-AAT-AC
(64 degeneracies) G G C C C

A
G

FIG. 4

SUBSTITUTE SHEET

6 / 8






FIG. 6



SUBSTITUTE SHEET

7 / 8

pTZRLuc-1Direction of translation 

RBS - ribosome binding site

FIG. 7

SUBSTITUTE SHEET

8 / 8

pTZRLuc-1 cells in 10mM EDTA pH8

Freeze thaw
once, lysozyme,
DNase I,
sonication

Centrifugation 48 x g, 30 min

discard pellet

DEAE Sephadex

Run in 1X, elute in
10X Standard
Buffer, pool
activity,
concentrate by
Amicon Filtration

G-100 Sephadex

Run in 1X
Standard Buffer,
pool activity,
concentrate by
Amicon filtration

Benzoic Acid Sepharose 1

Elute with 0.1M
Sodium Benzoate in
10X Standard Buffer,
dialyze against 1X
Standard Buffer

Benzoic Acid Sepharose 2

Elute with 0 to 0.5M
Sodium Benzoate
gradient in 10X
Standard Buffer,
dialyze against 1X
Standard Buffer
Amicon Filtration

Pure Recombinant Luciferase

FIG. 8

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/01614

I. CLASSIFICATION OF SUBJECT MATTER (In special classification systems, indicate page 2)		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 9/02, 15/00, 15/11, 15/53, 15/70, 15/74 U.S. CL.: 435/6, 189, 252.3, 252.33, 320.1; 436/63, 543; 536/27		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S.	69.1 435/6, 189, 252.3, 252.33, 320.1; 436/63, 543; 536/27	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
APS, Chemical Abstracts/STN, Biosis/DIALOG databases		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	BIOCHEMISTRY, Vol. 16, No. 1, issued 11 January 1977, MATTHEWS, ET AL., "Purification and Properties of <i>Renilla reniformis</i> Luciferase", pages 85-91, especially pages 86-89.	1-9 and 15-16
Y	NUCLEIC ACIDS RESEARCH, Vol. 11, No. 8, issued 25 April 1983, JAYE ET AL., "Isolation of a human anti-haemophilic factor IX cDNA clone using unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX", pages 2325-2335, especially pages 2326-2331 and 2334-2335.	1-9 and 15-16
Y	FEBS LETTERS, Vol. 126, No. 1, issued April 1981, MATSUDA ET AL., "The Primary Structure of L-1 Light Chain of Chicken Fast Skeletal Muscle Myosin and its Implication", pages 111-113, see entire document.	1-9 and 15-16
Y	WO, A, 87/03304 (McELROY ET AL.) 04 June 1987, especially pages 16-29.	1-9 and 15-16
Y	US, A, 4,956,190 (WOO ET AL.) 23 October 1990, especially columns 3 through 17.	14
(cont.)		
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claims or which is cited to establish the prior art date of a cited or citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>¹¹ later document published after the international filing date or priority date and not in conformity with the application but cited for supporting the preamble or claims comprising the invention</p> <p>¹² document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>¹³ document of particular relevance the claimed invention cannot be considered to practice an inventive step when the document is considered with or in more other such documents, such combination being necessary for a person skilled in the art</p> <p>X document number of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Filing of this International Search Report
19 July 1991		31 JUL 1991
International Searching Authority		Signature of International Searching Authority
ISA/US		William W. Moore (vsh)

Form PCT/US 212 (Rev. 11/87)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

Claims 1-14 describe a first Product and Methods of its Making and Use.
 Claims 15-17 describe a second Product of that first Method of Making and a Method of Use of the latter product.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. **telephone practice**
 2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

 3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

 4. ☐ As all search fees (which could be searched without effort) positing an additional fee, the International Searching Authority did not make payment of any additional fee.
- Remarks on Protest
- ☐ If no additional search fees were accompanied by applicant's protest.
 - ☐ No protest accompanied the payment of additional search fees.